Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8

Jordi Berenguer, Tonny Lagerweij, Xi Wen Zhao, Sophie Dusoswa, Petra van der Stoop, Bart Westerman, Mark C. de Gooijer, Marloes Zoetemelk, Anoek Zomer, Matheus H.W. Crommentuijn, Laurine E. Wedekind, Àlan López-López, Alberta Giovanazzi, Marina Bruch-Oms, Ida H.van der Meulen-Muileman, Rogier M. Reijmers, Toin H. van Kuppevelt, Juan Jesús García-Vallejo, Yvette van Kooyk, Bakhos A. TannousPieter Wesseling, Danijela Koppers-Lalic, W. Peter Vandertop, David P. Noske, Victor W. van Beusechem, Jacco van Rheenen, D. Michiel Pegtel, Olaf van Tellingen, Thomas Wurdinger

Research output: Contribution to journalArticleAcademicpeer-review

63 Citations (Scopus)


Cancer cells release extracellular vesicles (EVs) that contain functional biomolecules such as RNA and proteins. EVs are transferred to recipient cancer cells and can promote tumour progression and therapy resistance. Through RNAi screening, we identified a novel EV uptake mechanism involving a triple interaction between the chemokine receptor CCR8 on the cells, glycans exposed on EVs and the soluble ligand CCL18. This ligand acts as bridging molecule, connecting EVs to cancer cells. We show that glioblastoma EVs promote cell proliferation and resistance to the alkylating agent temozolomide (TMZ). Using in vitro and in vivo stem-like glioblastoma models, we demonstrate that EV-induced phenotypes are neutralised by a small molecule CCR8 inhibitor, R243. Interference with chemokine receptors may offer therapeutic opportunities against EV-mediated cross-talk in glioblastoma.

Original languageEnglish
Article number1446660
JournalJournal of extracellular vesicles
Issue number1
Publication statusPublished - 13 Mar 2018


  • CCR8
  • Chemokine receptor
  • Extracellular vesicles
  • RNAi screening
  • glioblastoma
  • glycans
  • temozolomide
  • therapy resistance

Cite this